{
  "image_filename": "table_p7_det_6_004.png",
  "image_path": "Hsiao_et_al.__2023_/extracted/figures/table_p7_det_6_004.png",
  "image_type": "Table",
  "page_number": 7,
  "block_id": "det_6_004",
  "claim_id": "claim_003",
  "claim": "Recombinant technology leads to a broader immune response that may provide cross-protection, even in a mismatch season.",
  "supports_claim": false,
  "explanation": "A table listing participant demographic and clinical characteristics (age, sex, race/ethnicity, preexisting illnesses, and prior influenza vaccination) for two vaccine groups (recombinant and standard-dose) and the overall study population, with footnotes and partial adjacent text about relative vaccine effectiveness outcomes. The table only presents baseline demographic and clinical characteristics and does not include any data on immune response breadth, cross-protection, or mismatch-season effectiveness, so it does not support the claim. Note: Limited to baseline characteristics; no immunogenicity or mismatch-season cross-protection data are provided in the visible portion.",
  "model_used": "o4-mini",
  "detailed_analysis": {
    "supports_claim": false,
    "image_description": "A table listing participant demographic and clinical characteristics (age, sex, race/ethnicity, preexisting illnesses, and prior influenza vaccination) for two vaccine groups (recombinant and standard-dose) and the overall study population, with footnotes and partial adjacent text about relative vaccine effectiveness outcomes.",
    "evidence_found": null,
    "reasoning": "The table only presents baseline demographic and clinical characteristics and does not include any data on immune response breadth, cross-protection, or mismatch-season effectiveness, so it does not support the claim.",
    "confidence_notes": "Limited to baseline characteristics; no immunogenicity or mismatch-season cross-protection data are provided in the visible portion."
  }
}